a Blue chip investor and micro cap trader.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Long Term Capital Gains?
Good timing there!
Most of my shares are in a IRA, but my CLRBZ and CLRBW are spread between IRA and taxable trading account. I will owe more capital gains taxes on some accounts. But that is a nice problem!
A couple more months and
...There will be 35 new screen names posting away here like happy kids in a schoolyard at recess!
Maybe I under estimate the size of the new crowd. And they will not know or care who we are nor how long we waited for the party. But they are essential to my retirement plans!!!
Look forward to being anonymous here! LOL
Spiking ...eom
Today flippers out, shorts in
but with CLRB GOOD FOR MM AND GOOD FOR- chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), lymphoplasmacytic lymphoma (LPL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), and potentially diffuse large B-cell lymphoma (DLBCL)- then WIN WIN for PATIENTS and investors.
If then: $30 pps to €32 pps?
Sold all when .20 was broken.
September Phase II results are optimistic,
BUT LOOK AT THE NUMEROUS DISEASES THAT ARE INCLUDED IN THE PHASE II TRIAL!
The PATIENTS potentially benefited and the REVENUE POTENTIAL of a successful Phase II trial for CLR131 have just gone up 5 FOLD...500%, in me humble opinion.
CLRB PRICE PER SHARE JUST WENT FROM $7.50 TO ABOUT $40 in my opinion.
NEWS: ORR is primary objective in Phase II trials...
MADISON, Wis., March 30, 2017 (GLOBE NEWSWIRE) -- Madison, Wis. Cellectar Biosciences, Inc. (CLRB), an oncology-focused clinical stage biotechnology company, today announces the initiation of a Phase II clinical study of its lead phospholipid drug conjugate (PDC) CLR 131 in patients with multiple myeloma and other hematologic malignancies.
The study will be conducted in up to 15 centers in the United States for patients with a variety of orphan-designated relapse or refractory hematologic cancers. The study’s primary endpoint is objective response rate (ORR) with additional endpoints of progression free survival (PFS), median overall survival (OS) and other markers of efficacy following a single 25.0 mCi/m2 dose of CLR 131, with the option for a second 25.0 mCi/m2 dose approximately 75-180 days later. Cellectar will receive approximately $2 million in a non-dilutive grant to help fund the trial from the National Cancer Institute and initial efficacy data are expected as early as the second half of 2017..."
https://finance.yahoo.com/news/much-anticipation-cellectar-biosciences-initiates-123000079.html
CLR 124 news was a flash in the pan,
but someday soon the CLRB shorts will go from the frying pan to the fire.
http://ih.advfn.com/p.php?pid=nmona&article=74144227&symbol=CLRB
The CLRB shorts are doomed, IMHO eom
TA: the next two waves up are the BIG ones,
from a technical analysis point of view, likely corresponding to Phase 1 COHORT 4 and then initial Phase II NEWS LATE IN THE SUMMER.
I SURE HOPE THE NEWS WILL BE VERY GOOD IN AUGUST/SEPTEMBER.
Otherwise a lot of money and patient lives are in serious risk.
GLTAL AND MM PATIENTS!!!
ORR IS NOT COMPREHENSIVE MEASURE OF DRUG ACTIVITY:
https://www.biooncology.com/clinical-trials/efficacy-endpoints.html
Cshom67: glad to hear you aren't short anymore,
but your comments on CLRB are still as negative as ever. At least you post some REASONS for your negative read. Looking at your IHUB PROFILE, it looks like you have posted 25 times only on CLRB- all during the latest CLRB RALLY back from around $1.25 pps.
We have had a 100% gain during that time. It reminds me of the legend of Cassandra: "Beware of Greeks bearing gifts!"
Please keep posting your thoughts on CLRB as they are timely and really seem to help. ;))
Shorty strikes back @ $3.00
Tomorrow is the S.T. MAKE OR BREAK DAY!
Remember: CLRBW @.30 and CLRBZ @ .95
...To leverage LONG CLRB with less cash upfront!!!
Short Squeeeeze.....and the 15th is next!
Tomorrow is the Roth Conference presentation in California followed by:
https://finance.yahoo.com/news/cellectar-biosciences-host-conference-call-133000004.html
Snakers: I wonder about CLR 131:
The delivery platform is targeted very nicely to say the least.
But I wonder about the payload: Radio active Iodine 131.
Specifically, how is the human Thyroid protected from absorbing too much 131?
I know about the medicial half life of about a week. But...?
3-15-17 will be a busy day for CLRB,
with a CEO presentation at a conference out in California and then this 4th Quarter 2016 Conference Call.
Both seem a little too soon to reveal new clinical trial news except for recruitment for on-going trials.
$3 is a foregone conclusion in March,
...So targeting April is an easy $4.
It is all in the clinical trial cards...
Post Script:
From the last paragraph of the CLRB 2/27/17 press release:
"...The company recently brought forward guidance for the initiation of its NCI-supported Phase II trial in multiple myeloma and other selected hematologic cancers to the first quarter of 2017..."
The company expressly has stated above that its platform will be use to attack various other blood cancers and even solid tumors with various linked payloads! Of course that will take much money and more time. What better way than to sell rights to commercialize CLR 131 through a deep pockets 3rd party and thereby fund its broader vision and other payloads for CLRB's patented platform?
WIN, WIN- especially for the sick patients!
Snakers: "Another strong move toward acquisition":
Today's PR reads in relevant part:
"...WARF has been, and continues to be, an investor in Cellectar and has been a joint owner, with Cellectar, of the MOU patent filing for CLR 131 for the treatment of multiple myeloma. While the company has always maintained the rights to develop and commercialize CLR 131 for multiple myeloma, the execution of this licensing agreement provides the company with exclusive rights to the development and commercialization of the compound in multiple myeloma..."
So as a result of this new and limited licensing agreement, WARF can no longer use it ownership of the MOU patent rights on CLR. 131 to control any development & commercialization of CLR 131 in the "treatment of Multiple Myeloma".
A few things leap to mind:
1. What was the legal consideration to WARF and/or to CLRB in exchange for this new licensing agreement?
2. What was the motive for such a new licensing agreement?
The answer to question #1is likely inherent in the answer to question #2:
There is clear and present interest by a third party in acquiring the rights to commercialize CLR 131 as to just its application to Multiple Myeloma!? And that 3rd party does not want to have to deal with contingencies of a co-owner of the rights sought for purchase, especially a public university affiliate.
If there is a deep pockets third party who wants to commercialize just the MM APPLICATION of this CLRB platform, then CLRB could thereby significantly and exclusively capitalize this same biotechnology for OTHER blood and solid tumor cancers, using the funding from the third party on just a MM deal.
This would address the criticism expressed here by posters that CLRB does not have the capital to match its burn rate!
3. Who is likely to be this third party buyer? The answer can be found by reviewing those companies already focused on MM. Celegene comes to mind. But there are other and smaller suspects!
THE PLOT THICKENS AND THE CLRB PRICE CLIMBS!!!
Yes, the news is snowballing over the shorts:
MADISON, Wis., Feb. 27, 2017 (GLOBE NEWSWIRE) -
"...The data from Cohort 3 show that the 25 mCi/m2 dose was safe and well tolerated, and those patients experienced a similar adverse event profile to that experienced by patients in the previous two cohorts. The average grade of adverse event by patient was 2.57 in Cohort 3, compared to Cohorts 1 and 2 with average grades of 2.05 and 2.71, respectively. Cohort 3 patients experienced an average of seven adverse events compared to Cohorts 1 and 2 with 4.75 and 4.25 events respectively. However, there were no unexpected adverse events and those adverse events experienced by patients were both predictable and manageable.
All four Cohort 3 patients achieved stable disease and continue to be followed for progression-free survival (PFS) and median overall survival (mOS). It is important to note, that similar to Cohort 2 vs. Cohort 1, patients in Cohort 3 experienced a more substantial and sustained reduction in m-protein, a surrogate marker of efficacy. The company expects to provide a more extensive efficacy data update for Cohort 3 in the near term.
While it is also premature to report survival-related efficacy data from Cohort 3, all patients in Cohorts 1 and 2 continue to experience overall survival benefit. Patients from Cohort 1, who received a single 12.5 mCi/m2 dose, have experienced, to date, mOS of 17.7 months. Cohort 2 patients, who received a single 18.75 mCi/m2 dose, have a current median overall survival of 8.4 months. Based on this data, the company has the option of using an 18.75 mCi/m2 single or multi-dose regimen as monotherapy or in combination with other agents as a therapeutic dose in future clinical studies evaluating efficacy. Importantly, median overall survival for all evaluable patients in each cohort continues to increase, and the company will continue to follow these patients to determine the full extent of the overall survival benefit of CLR 131..."
And so they are starting the Phase 2 CLR 131 clinical trial at the Phase 1 2nd COHORT dosage WITH and without Dex. at up to 15 centers across the country:
"...The company recently brought forward guidance for the initiation of its NCI-supported Phase II trial in multiple myeloma and other selected hematologic cancers to the first quarter of 2017. As the study is currently designed, all patients will receive, at a minimum, a single dose of CLR 131 at 25 mCi/m2 infused over approximately 30 minutes, with the option of a second 25 mCi/m2 dose 75-180 days later, based upon physician assessment. The Phase II study will be conducted in up to 15 centers across the United States and Cellectar anticipates initial efficacy data as early as the second half of 2017..."
LOOK OUT SHORTY!
SHORT SQUEEZE ALL MONTH LONG,
get use to it Shorty...buy back your shares or die!
Kissed $2.50 without news,
but imagine what it will do with WITH REAL CLINICAL TRIAL NEWS IN A FEW MONTHS!
KISS $7.50 pps? Or is that too low?
Snakers: thanks for the brilliant reply!
It is a reasonable assessment of buyout price per share. It avoids the overly bearish and bullish sentiment on this board by various posters. And it leaves room to trade the fluxuations in price. Brilliant and honest.
I will send you some private thoughts and information after I buy an IHUB premium membership in a few days.
Hypothetically speaking, what would be a fair
...Purchase price per share?
"Wild ass guess" would do...
Very well said, Snakers!
JUNO, on the one end, gave up on that approach, while KITE has not had been stopped by adverse events.
Cost on one end and beneficial result on the other. Now the best of all worlds would be low cost and very beneficial results. CLRB could be the latter, for many diseases- not just MM. Bonus!
Then, the ARE longs on one end and SHORTS on the other end. ORR WILL EVENTUALLY MAKE A BIG DIFFERENCE FOR PATIENTS AND TRADERS!
Shorty Doesn't Giveup!
Selling shares they don't have is... Dangerous
CLRB was being taken down in last minute,
But someone bought 11,230 shares at the close to bring it up a bit from where it was.
It is just a true observation, not an opinion or conclusion...except for the possible relationship posited to the PR.
GLTAL
Free market analysis: buy the close?
The last 5 minutes of trading will tell us what "the market", as a whole, thinks about today's press release.
The same may be very true about the first 5 minutes of trading tomorrow.
Word to the wise, for free!
Thanks for the early news post, AO!
This paragraph was of the most interest to me:
"...While it is also premature to report survival-related efficacy data from Cohort 3, all patients in Cohorts 1 and 2 continue to experience overall survival benefit. Patients from Cohort 1, who received a single 12.5 mCi/m2 dose, have experienced, to date, mOS of 17.7 months. Cohort 2 patients, who received a single 18.75 mCi/m2 dose, have a current median overall survival of 8.4 months. Based on this data, the company has the option of using an 18.75 mCi/m2 single or multi-dose regimen as monotherapy or in combination with other agents as a therapeutic dose in future clinical studies evaluating efficacy. Importantly, median overall survival for all evaluable patients in each cohort continues to increase, and the company will continue to follow these patients to determine the full extent of the overall survival benefit of CLR 131. ." .
A FEW MORE FAVORABLE PRESS RELEASES LIKE THIS ONE WITH SPECIFFIC THERAPUTICAL FACTS INCLUDED, AND THE MARKET WILL WAKE UP TO THIS BIOTECH!
SOW & RYMAN: evidence CLRB ahead of schedule,
From a recent CLRB press release:
"...Initiation of the fourth cohort occurs well ahead of the company's guidance, which called for initiation to occur at the end of the second quarter of 2017. Further, the company continues to follow all 12 evaluable patients in each of the three previously completed cohorts, which include eight patients from Cohorts 1 and 2 who continue to extend median overall survival. Cellectar expects to provide a detailed data update on these patients by the end of the second quarter of 2017..."
Ryman: I think Phase 2 is running now,
at least on B cell MM malignancies with CLR131 AND Dexamethasone:
"...In addition, the company plans to initiate a Phase II clinical study to assess efficacy in a range of B-cell malignancies in the first quarter of 2017..."
Anyway, I saw mention from the company this year that they had their first patient recruited in January, and thought it said for Phase 2 trial mentioned above. With relapsed MM you do not wait to get more recruits to all start together. You get started!
Correct me if I am wrong...
July first is the earliest Phase 2 Update,
http://cellectar.com/pdc-pipeline/
I will post a better chart from the company:
"...In addition, the company recently brought forward guidance for the initiation of its NCI-supported Phase II trial in multiple myeloma and other selected hematologic cancers to the first quarter of 2017. The company expects that all patients will receive a single dose of CLR 131 at 25 mCi/m2 infused over approximately 30 minutes, with the option of a second 25 mCi/m2 dose 75-180 days later, based upon physician assessment. The Phase II study will be conducted in up to 15 centers across the United States and Cellectar anticipates initial efficacy data as early as the second half of 2017..."
This is getting to be a great board!
Thank you all for participating.
Excitement can be good or bad. BUT IT WILL BE GETTING VERY EXCITING HERE AND SOON. COHORT 3 OF PHASE 1 DOES HAVE RESULTS FOR US. YOU HAVE EXPLAINED THE CURRENT DIP PERFECTLY.
REMEMBER CLRB IS STARTING NOT ONLY COHORT 4, BUT ALSO A CLR131 PHASE 2 CLINICAL TRIAL HAS ALREADY STARTED AND RESULTS ARE DUE 7-1-17... THAT IMPLIES A BUNCH OF HOPEFULLY GOOD NEWS.
AND AT LEAST THEY HAVE NOT ANNOUNCED A JUNO TYPE TRAGEDY WITH PATIENTS DYING FROM ANY TRIAL. THE CLR131 PATIENTS DESERVE GOOD NEWS MORE THAN WE DO.
Ryman, I agree with you on that,
...Still an early to mid stage developmental biotech.
Sold some CRLB and CLRBW in the $1.55 and .36 ranges respectively.
So I can reload on next significant bottom.
Exploit Da Bears!
Yup, exploit Da Bears,
they deserve no mercy because they gave no mercy.
Take advantage of them: buy low, SELL HIGH!
HINT: THIS IS NOT HIGH- OVER $4 PPS IS GETTING HIGH...
Light volume so far,
Happy Hour lasted 2 minutes...consolidation seems to be the soup of the day.
Film at Eleven...
Typical Happy Hour opening spike,
let's see if the bulls or bears are in charge today.
WILL THE TREND REMAIN UP?
Well, this sounds very positive,
quoting from today's press release:
"Our enthusiasm for CLR 131’s potential in multiple myeloma patients continues to grow given the positive safety, efficacy markers, progression-free survival and median overall survival results that we have observed to date in the Phase I trial, particularly given such a heavily pretreated patient population,” said Jim Caruso, president and CEO of Cellectar Biosciences. “We will explore the potential enhanced clinical benefits of a two-dose regimen in our imminent Phase II study, and look forward to updating investors on results of the fourth cohort when available.”